Braidwell LP Invests $9.91 Million in Immunic, Inc. $IMUX

Key Points

• Braidwell LP acquired 645,010 Immunic shares valued at approximately $9.91 million, giving it a 4.73% stake. Institutional investors collectively own 51.82% of the company.
• Immunic shares opened at $14.24 after declining 2.3%; the stock has traded between $5.06 and $17.43 over the past year. The company reported a quarterly loss of $0.80 per share, better than the $1.16 loss analysts expected.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $47.25 price target, despite one sell rating. Immunic is developing oral therapies, including Phase 2 candidate IMU-838 for multiple sclerosis, ulcerative colitis and Crohn’s disease.

Braidwell LP bought a new position in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 645,010 shares of the company's stock, valued at approximately $9,914,000. Braidwell LP owned 4.73% of Immunic as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of IMUX. CTC Alternative Strategies Ltd. purchased a new position in Immunic during the 1st quarter worth approximately $27,000. Qube Research & Technologies Ltd purchased a new stake in shares of Immunic in the 3rd quarter valued at $29,000. ADAR1 Capital Management LLC purchased a new stake in shares of Immunic in the 1st quarter valued at $33,000. Two Sigma Investments LP acquired a new stake in shares of Immunic in the third quarter worth $52,000. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Immunic in the fourth quarter worth $83,000. Hedge funds and other institutional investors own 51.82% of the company's stock.

Immunic Trading Down 2.3%

Shares of IMUX opened at $14.24 on Thursday. The firm has a market cap of $194.23 million, a P/E ratio of -3.25 and a beta of 1.41. Immunic, Inc. has a 12 month low of $5.06 and a 12 month high of $17.43. The stock's 50 day moving average is $15.05 and its two-hundred day moving average is $12.94.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.36. Equities research analysts forecast that Immunic, Inc. will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Immunic in a research report on Wednesday, August 26th. Wedbush assumed coverage on Immunic in a research report on Monday, August 17th. They set an "outperform" rating and a $45.00 price target on the stock. LADENBURG THALM/SH SH upgraded Immunic to a "strong-buy" rating in a research note on Wednesday, July 29th. Roth Capital reissued a "buy" rating on shares of Immunic in a report on Tuesday. Finally, Wolfe Research began coverage on Immunic in a research note on Friday, May 22nd. They issued an "outperform" rating on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $47.25.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source